Requires performance testing and disclosure of image analysis algorithms used in medical image analyzers that help detect abnormalities during a patient radiograph.
Requires disclosure of inputs, outputs, components, and limitations of image analysis algorithms used in medical image analyzers.
Requires performance testing that demonstrates the algorithms meaningfully improve the detection of abnormalities during patient radiographs.
Requires appropriate software documentation including device hazard analysis, software specs, traceability analysis, pass/fail criteria, and cybersecurity.
Requires a detailed summary of the methodology behind the performance testing.
Key facts
🏛️ This document has been enacted by the U.S. Food and Drug Administration.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the private sector, rather than the government.
📜 This document's name is 21 CFR § 892.2070 ("Medical image analyzer").
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that address whether humans can understand (a) the mechanisms underlying an AI system’s operation and/or (b) the meaning of the systems’ output in the context of use.
This tag applies to documents that address the ability of an AI system to perform as required, without failure, under the conditions of expected use and over a given period of time, including the entire lifetime of the system.
This tag applies to documents that govern the security of digital systems associated with AI, including systems involved in development and training, systems housing related intellectual property, and computing infrastructure for deployed models.
This tag applies to documents that govern whether, how, and/or to what extent people who are affected by or otherwise have an interest in an AI system have access to relevant information about the system.
This tag applies to documents that require, encourage, etc. the disclosure of information about AI systems by their users, developers, vendors, or others directly involved with the systems to third parties, including but not limited to the general public.
This tag applies to documents that address the form of disclosure of information about AI systems, such that information is required or encouraged to be disclosed in a prescribed, standardized form intended to make the information easily accessible and understandable.
This tag applies to documents that discuss evaluations that assess whether deployed AI systems meet the expectations specified or claimed prior to deployment.
This tag applies to documents that require or incentivize AI systems to incorporate specific features or achieve (or not achieve) specified results in operation, or to be used or not to be used in specified ways or for specific purposes. Requirements may be defined objectively (e.g., systems must score above a certain level on an established benchmark, systems must incorporate a certain technical feature) or subjectively (e.g., systems must not demonstrate undue bias).
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
§ 892.2070 Medical image analyzer.
(a) Identification.
Medical image analyzers, including computer-assisted/aided detection (CADe) devices for mammography breast cancer, ultrasound breast lesions, radiograph lung nodules, and radiograph dental caries detection, is a prescription device that is intended to identify, mark, highlight, or in any other manner direct the clinicians' attention to portions of a radiology image that may reveal abnormalities during interpretation of patient radiology images by the clinicians. This device incorporates pattern recognition and data analysis capabilities and operates on previously acquired medical images. This device is not intended to replace the review by a qualified radiologist, and is not intended to be used for triage, or to recommend diagnosis.
Identifies and highlights abnormalities in radiology images, assisting but not replacing radiologist interpretation.
Identifies and highlights abnormalities in radiology images, assisting but not replacing radiologist interpretation.
(b) Classification.
Class II (special controls). The special controls for this device are:
(1) Design verification and validation must include:
(i) A detailed description of the image analysis algorithms including a description of the algorithm inputs and outputs, each major component or block, and algorithm limitations.
(ii) A detailed description of pre-specified performance testing methods and dataset(s) used to assess whether the device will improve reader performance as intended and to characterize the standalone device performance. Performance testing includes one or more standalone tests, side-by-side comparisons, or a reader study, as applicable.
(iii) Results from performance testing that demonstrate that the device improves reader performance in the intended use population when used in accordance with the instructions for use. The performance assessment must be based on appropriate diagnostic accuracy measures (e.g., receiver operator characteristic plot, sensitivity, specificity, predictive value, and diagnostic likelihood ratio). The test dataset must contain a sufficient number of cases from important cohorts (e.g., subsets defined by clinically relevant confounders, effect modifiers, concomitant diseases, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals of the device for these individual subsets can be characterized for the intended use population and imaging equipment.
(iv) Appropriate software documentation (e.g., device hazard analysis; software requirements specification document; software design specification document; traceability analysis; description of verification and validation activities including system level test protocol, pass/fail criteria, and results; and cybersecurity).
Requires Class II devices to verify design, validate performance, test diagnostic accuracy, and document software.
Requires Class II devices to verify design, validate performance, test diagnostic accuracy, and document software.
(2) Labeling must include the following:
(i) A detailed description of the patient population for which the device is indicated for use.
(ii) A detailed description of the intended reading protocol.
(iii) A detailed description of the intended user and user training that addresses appropriate reading protocols for the device.
(iv) A detailed description of the device inputs and outputs.
(v) A detailed description of compatible imaging hardware and imaging protocols.
(vi) Discussion of warnings, precautions, and limitations must include situations in which the device may fail or may not operate at its expected performance level (e.g., poor image quality or for certain subpopulations), as applicable.
(vii) Device operating instructions.
(viii) A detailed summary of the performance testing, including: test methods, dataset characteristics, results, and a summary of sub-analyses on case distributions stratified by relevant confounders, such as lesion and organ characteristics, disease stages, and imaging equipment.
Requires labeling to describe patient population, reading protocol, user training, device specifications, warnings, and performance testing.
Requires labeling to describe patient population, reading protocol, user training, device specifications, warnings, and performance testing.